Biogen, Elan seek okay for first-line Tysabri use in MS

LONDON (Reuters) - Biogen Idec and Elan have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis, a move that could boost sales of the drug.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news